Current guidelines and prioritizing treatment of hepatitis C virus in HIV-infected patients

Current Opinion in HIV and AIDS

Volumn 10, Issue 5, 2015, Pages 323-329

  Feeney, Eoin R ^a   Chung, Raymond T ^b   Yazdanpanah, Yazdan ^c,d,e  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DIDEROT   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cirrhosis; Direct acting antivirals; Hepatitis C virus; HIV

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; DASABUVIR; DIRECT ACTING ANTIVIRUS AGENT; EFAVIRENZ; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; DRUG COST; HEALTH CARE PLANNING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; COINFECTION; COMPLICATION; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; COINFECTION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84942872986     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000178     Document Type: Review

References (43)

1. Soriano V, Vispo E, Labarga P, et al. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85:303-315.
2. Amin J, Kaye M, Skidmore S, et al. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004; 5:174-179.
3. Fierer DS, Dieterich DT, Fiel MI, et al. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis 2013; 56:1038-1043.
4. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36:491-498.
5. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
6. Mira JA, Rivero-Juarez A, Lopez-Cortes LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013; 56:1646-1653.
7. Tural C, Galeras JA, Planas R, et al. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients. Antivir Ther 2008; 13:1047-1055.
8. Perez-Olmeda M, Soriano V, Asensi V, et al. Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. AIDS Res Hum Retroviruses 2003; 19:1083-1089.
9. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-88.
10. Brook G, Main J, Nelson M, et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 2010; 11:1-30.
11. Kuehne FC, Bethe U, Freedberg K, Goldie SJ. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med 2002; 162:2545-2556.
12. Campos NG, Salomon JA, Servoss JC, et al. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med 2007; 120:272-279.
13. Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 2011; 29:993-1003.
14. Elazar M, Glenn JS. HCV NS5A inhibitors: the devil is in the details. Gastroenterology 2014; 147:273-277.
15. Hoofnagle JH, Sherker AH. Therapy for hepatitis C: the costs of success. N Engl J Med 2014; 370:1552-1553.
16. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159:86-96.
17. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597-605.
18. Beste LA, Green PK, Ioannou GN. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. Eur J Gastroenterol Hepatol 2015; 27:123-129.
19. Butt AA, Yan P, Shaikh OS, et al. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat 2014. [Epub ahead of print]
20. Miailhes P, Gilbert C, Lacombe K, et al. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients. Liver Int 2015. [Epub ahead of print]
21. Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV- 1: a phase 3 study. Clin Infect Dis 2014; 59:1579-1587.
22. Lenz O, Verbinnen T, Fevery B, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol 2015; 62:1008-1014.
23. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
24. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310:804-811.
25. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312:353-361.
26. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, nonrandomised, phase 3 study. Lancet 2015; 385:1098-1106.
27. EASL. Recommendations on treatment of hepatitis C. http://www.easl.eu/ research/our-contributions/clinical-practice-guidelines/detail/recommendations- on-treatment-of-hepatitis-c-2015/report/4. [Accessed 5 May 2015]
28. Gilmore J, Lynn K, Breen D, et al. Effectiveness of sofosbuvir/simeprevir for HIV/HCV patients in clinical practice, abstract 645. Conference on Retroviruses and Opportunistic Infections, Seattle, February 23-26 2015.
29. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-1898.
30. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-1493.
31. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-221.
32. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313:1232-1239.
33. Naggie S, Cooper C, Saag M, et al. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1. Abstract 152LB. Conference on Retroviruses and Opportunistic Infections, Seattle, February 23-26, 2015.
34. Wyles D, Ruane P, Sulkowski M, et al.Daclatasvir in combination with sofosbuvir for HIV/HCV coinfection: ALLY-2 Study. Abstract 151LB. Conference on Retroviruses and Opportunistic Infections, Seattle, February 23-26 2015.
35. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61:1127-1135.
36. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313:1232-1239.
37. EACS. Guidelines Version 7.1 November 2014. http://www.eacsociety.org/ files/guidelines-7.1-english.pdf. [Accessed 7 June 2015]
38. Vogel M, Boesecke C, Rockstroh JK. Acute hepatitis C infection in HIVpositive patients. Curr Opin Infect Dis 2011; 24:1-6.
39. Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011; 60:837-845.
40. Deuffic-Burban S, Schwarzinger M, Obach D, et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). J Hepatol 2014; 61:7-14.
41. Younossi ZM, Singer ME, Mir HM, et al. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60:530-537.
42. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015; 162:397-406.
43. Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvirbased regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015; 162:619-629.